Key PointsQuestionWhat is the benefit of bone-targeted radioisotope (RI) use in metastatic castration-resistant prostate cancer, and is there any difference between α-emitting and β-emitting RIs? FindingThis meta-analysis of individual patient data was based on 6 randomized clinical trials including 2081 patients that compared RI use with no RI use study arms with no overall significant difference. While an α-emitting RI (radium 223) was significantly associated with higher overall survival and higher symptomatic skeletal event–free survival, a β-emitting RI (strontium-89) was not associated with these outcomes. MeaningThis meta-analysis suggests a benefit of α-emitting RIs but not of β-emitting RIs for overall survival and symptomatic skeletal event–free survival, although caution is necessary for generalizability of these results, given the between-trial heterogeneity.
JAMA Oncology – American Medical Association
Published: Feb 12, 2020